These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 20522598)

  • 1. Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.
    Nin JW; Jorsal A; Ferreira I; Schalkwijk CG; Prins MH; Parving HH; Tarnow L; Rossing P; Stehouwer CD
    Diabetes; 2010 Aug; 59(8):2027-32. PubMed ID: 20522598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.
    Nin JW; Jorsal A; Ferreira I; Schalkwijk CG; Prins MH; Parving HH; Tarnow L; Rossing P; Stehouwer CD
    Diabetes Care; 2011 Feb; 34(2):442-7. PubMed ID: 21270199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study.
    Nin JW; Ferreira I; Schalkwijk CG; Prins MH; Chaturvedi N; Fuller JH; Stehouwer CD;
    Diabetologia; 2009 Apr; 52(4):705-14. PubMed ID: 19183936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12 year follow-up study.
    Nin JW; Ferreira I; Schalkwijk CG; Jorsal A; Prins MH; Parving HH; Tarnow L; Rossing P; Stehouwer CD
    Diabetologia; 2012 Sep; 55(9):2489-93. PubMed ID: 22752054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients.
    Isoyama N; Leurs P; Qureshi AR; Bruchfeld A; Anderstam B; Heimburger O; Bárány P; Stenvinkel P; Lindholm B
    Nephrol Dial Transplant; 2015 Jan; 30(1):84-91. PubMed ID: 25074436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy.
    Lajer M; Jorsal A; Tarnow L; Parving HH; Rossing P
    Diabetes Care; 2010 Jul; 33(7):1567-72. PubMed ID: 20357380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial.
    Colhoun HM; Betteridge DJ; Durrington P; Hitman G; Neil A; Livingstone S; Charlton-Menys V; Bao W; Demicco DA; Preston GM; Deshmukh H; Tan K; Fuller JH
    Diabetes; 2011 Sep; 60(9):2379-85. PubMed ID: 21771973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher levels of the soluble receptor for advanced glycation end products and lower levels of the extracellular newly identified receptor for advanced glycation end products were associated with lipid-lowering drugs in patients with type 1 diabetes: a comparative cross-sectional study.
    Melin EO; Dereke J; Hillman M
    Lipids Health Dis; 2020 Oct; 19(1):223. PubMed ID: 33054750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.
    Tan KC; Shiu SW; Chow WS; Leng L; Bucala R; Betteridge DJ
    Diabetologia; 2006 Nov; 49(11):2756-62. PubMed ID: 16969649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein glycation products associate with progression of kidney disease and incident cardiovascular events in individuals with type 1 diabetes.
    Adeshara K; Gordin D; Antikainen AA; Harjutsalo V; Sandholm N; Lehto MJ; Groop PH;
    Cardiovasc Diabetol; 2024 Jul; 23(1):235. PubMed ID: 38965604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy.
    Galsgaard J; Persson F; Hansen TW; Jorsal A; Tarnow L; Parving HH; Rossing P
    Kidney Int; 2017 Nov; 92(5):1242-1248. PubMed ID: 28712855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease in Individuals With Type 1 Diabetes: A 12-Year Follow-up Study.
    Hanssen NMJ; Scheijen JLJM; Jorsal A; Parving HH; Tarnow L; Rossing P; Stehouwer CDA; Schalkwijk CG
    Diabetes; 2017 Aug; 66(8):2278-2283. PubMed ID: 28588100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study.
    Rebholz CM; Astor BC; Grams ME; Halushka MK; Lazo M; Hoogeveen RC; Ballantyne CM; Coresh J; Selvin E
    Nephrol Dial Transplant; 2015 Jan; 30(1):77-83. PubMed ID: 25147225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes.
    Thomas MC; Söderlund J; Lehto M; Mäkinen VP; Moran JL; Cooper ME; Forsblom C; Groop PH;
    Diabetologia; 2011 Oct; 54(10):2669-77. PubMed ID: 21607631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study.
    Peeters SA; Engelen L; Buijs J; Jorsal A; Parving HH; Tarnow L; Rossing P; Schalkwijk CG; Stehouwer CDA
    Cardiovasc Diabetol; 2017 Apr; 16(1):55. PubMed ID: 28446168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of the receptor for advanced glycation end products (RAGE) -374 T/A gene polymorphism and circulating soluble RAGE with nephropathy in type 1 diabetic patients.
    Abdel-Azeez HA; El-Okely AM
    Egypt J Immunol; 2009; 16(1):95-106. PubMed ID: 20726326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.
    Lajer M; Tarnow L; Jorsal A; Teerlink T; Parving HH; Rossing P
    Diabetes Care; 2008 Apr; 31(4):747-52. PubMed ID: 18162497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble form of receptor for advanced glycation end products and incidence of new cardiovascular events among patients with cardiovascular disease.
    Reichert S; Triebert U; Santos AN; Hofmann B; Schaller HG; Schlitt A; Schulz S
    Atherosclerosis; 2017 Nov; 266():234-239. PubMed ID: 28864204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients.
    Nakashima A; Carrero JJ; Qureshi AR; Miyamoto T; Anderstam B; Bárány P; Heimbürger O; Stenvinkel P; Lindholm B
    Clin J Am Soc Nephrol; 2010 Dec; 5(12):2213-9. PubMed ID: 20847094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma sRAGE is not associated with urinary microalbumin excretion in type 2 diabetic nephropathy at the early stage.
    Yu JY; An XF; Liu JS; Ten SC; Wang X; Zhao Y; Huang S; Gu WJ; Gao F
    Diabetes Res Clin Pract; 2010 Feb; 87(2):157-60. PubMed ID: 19945761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.